KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Accumulated Expenses: 2013-2024

Historic Other Accumulated Expenses for Xenon Pharmaceuticals (XENE) over the last 10 years, with Dec 2024 value amounting to $714,000.

  • Xenon Pharmaceuticals' Other Accumulated Expenses fell 13.43% to $935,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $935,000, marking a year-over-year decrease of 13.43%. This contributed to the annual value of $714,000 for FY2024, which is N/A change from last year.
  • Xenon Pharmaceuticals' Other Accumulated Expenses amounted to $714,000 in FY2024, which was up 109.38% from $341,000 recorded in FY2022.
  • In the past 5 years, Xenon Pharmaceuticals' Other Accumulated Expenses registered a high of $714,000 during FY2024, and its lowest value of $69,000 during FY2020.
  • Over the past 2 years, Xenon Pharmaceuticals' median Other Accumulated Expenses value was $527,500 (recorded in 2022), while the average stood at $527,500.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 64.62% in 2020, then spiked by 188.98% in 2022.
  • Over the past 4 years, Xenon Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $69,000 in 2020, then skyrocketed by 71.01% to $118,000 in 2021, then surged by 188.98% to $341,000 in 2022, then reached $714,000 in 2024.